[go: up one dir, main page]

FR2750866B1 - Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire - Google Patents

Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire

Info

Publication number
FR2750866B1
FR2750866B1 FR9608243A FR9608243A FR2750866B1 FR 2750866 B1 FR2750866 B1 FR 2750866B1 FR 9608243 A FR9608243 A FR 9608243A FR 9608243 A FR9608243 A FR 9608243A FR 2750866 B1 FR2750866 B1 FR 2750866B1
Authority
FR
France
Prior art keywords
avian
infectious laryngotracheitis
laryngotracheitis virus
living vaccine
recombinant living
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9608243A
Other languages
English (en)
Other versions
FR2750866A1 (fr
Inventor
Jean Christophe Franc Audonnet
Michel Joseph Marie Bublot
Michel Emile Albert Riviere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health France SAS
Original Assignee
Rhone Merieux SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Merieux SA filed Critical Rhone Merieux SA
Priority to FR9608243A priority Critical patent/FR2750866B1/fr
Priority to MA24675A priority patent/MA24222A1/fr
Priority to ARP970102799A priority patent/AR008620A1/es
Priority to ZA975618A priority patent/ZA975618B/xx
Priority to EP97930591A priority patent/EP0914458A1/fr
Priority to AU34487/97A priority patent/AU739374B2/en
Priority to PCT/FR1997/001138 priority patent/WO1997049826A1/fr
Priority to TNTNSN97109A priority patent/TNSN97109A1/fr
Priority to JP10502456A priority patent/JP2000512844A/ja
Priority to IDP972222A priority patent/ID18351A/id
Priority to CO97036155A priority patent/CO4700303A1/es
Priority to PE1997000548A priority patent/PE52599A1/es
Publication of FR2750866A1 publication Critical patent/FR2750866A1/fr
Application granted granted Critical
Publication of FR2750866B1 publication Critical patent/FR2750866B1/fr
Priority to US09/219,932 priority patent/US6153199A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR9608243A 1996-06-27 1996-06-27 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire Expired - Lifetime FR2750866B1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR9608243A FR2750866B1 (fr) 1996-06-27 1996-06-27 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
MA24675A MA24222A1 (fr) 1996-06-27 1997-06-23 Vaccin vivant recombinant aviaire utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire.
TNTNSN97109A TNSN97109A1 (fr) 1996-06-27 1997-06-25 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
EP97930591A EP0914458A1 (fr) 1996-06-27 1997-06-25 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
AU34487/97A AU739374B2 (en) 1996-06-27 1997-06-25 Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus
PCT/FR1997/001138 WO1997049826A1 (fr) 1996-06-27 1997-06-25 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
ARP970102799A AR008620A1 (es) 1996-06-27 1997-06-25 Vacuna viva recombinante, fragmento de adn y virus iltv que la componen
JP10502456A JP2000512844A (ja) 1996-06-27 1997-06-25 ベクターとして鳥類の感染性喉頭気管炎ウイルスを用いた鳥類用組換え生ワクチン
ZA975618A ZA975618B (en) 1996-06-27 1997-06-25 Avian recombinant live vaccine using as vector the avian infectious laryngotrachetis virus
IDP972222A ID18351A (id) 1996-06-27 1997-06-26 Vaksin hidup rekombinan avian, yang sebagai vektor menggunakan virus laringotracheitis menular avian
CO97036155A CO4700303A1 (es) 1996-06-27 1997-06-27 Vacuna viva recombinante aviaria que utiliza como vector el virus de la laringotraqueitis infecciosa aviaria
PE1997000548A PE52599A1 (es) 1996-06-27 1997-06-27 Vacuna viva recombinante aviaria, que comprende como vector el virus de la laringotraqueitis infecciosa
US09/219,932 US6153199A (en) 1996-06-27 1998-12-23 Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9608243A FR2750866B1 (fr) 1996-06-27 1996-06-27 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire

Publications (2)

Publication Number Publication Date
FR2750866A1 FR2750866A1 (fr) 1998-01-16
FR2750866B1 true FR2750866B1 (fr) 1998-11-27

Family

ID=9493649

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9608243A Expired - Lifetime FR2750866B1 (fr) 1996-06-27 1996-06-27 Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire

Country Status (13)

Country Link
US (1) US6153199A (fr)
EP (1) EP0914458A1 (fr)
JP (1) JP2000512844A (fr)
AR (1) AR008620A1 (fr)
AU (1) AU739374B2 (fr)
CO (1) CO4700303A1 (fr)
FR (1) FR2750866B1 (fr)
ID (1) ID18351A (fr)
MA (1) MA24222A1 (fr)
PE (1) PE52599A1 (fr)
TN (1) TNSN97109A1 (fr)
WO (1) WO1997049826A1 (fr)
ZA (1) ZA975618B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913751B2 (en) 1992-06-12 2005-07-05 Schering-Plough Veterinary Corporation Recombinant avian herpesvirus useful in vaccine production
EP1026246B1 (fr) * 1997-10-03 2006-11-29 Zeon Corporation Recombinants de virus herpetique infectieux aviaire et vaccins recombinants prepares avec ces derniers
AR031405A1 (es) * 2000-11-21 2003-09-24 Wyeth Corp Metodos y vacunas para conferir proteccion in ovo contra la rinotraqueitis del pavo
JP2002356441A (ja) * 2001-03-15 2002-12-13 Akzo Nobel Nv 組換え伝染性喉頭気管炎ウイルスワクチン
US7314715B2 (en) * 2001-06-14 2008-01-01 Schering-Plough Animal Health Corporation Recombinant avian herpesvirus useful in vaccine production
DE60230918D1 (de) 2001-11-16 2009-03-05 Biogen Idec Inc Polycistronische expression von antikörpern in cho zellen
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
EP1606419A1 (fr) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systemes et procedes pour accroitre la production de proteines et de lait chez des bovins laitiers
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
US20050214316A1 (en) 2003-11-13 2005-09-29 Brown Thomas P Methods of characterizing infectious bursal disease virus
MXPA06009452A (es) 2004-02-19 2007-03-15 Univ Alberta Polimorfismos del promotor de leptin y sus usos.
DE602006013117D1 (de) 2005-04-25 2010-05-06 Merial Ltd Nipah-virus-impfstoffe
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
WO2007056614A1 (fr) 2005-11-14 2007-05-18 Merial Limited Thérapie génique pour insuffisance rénale
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
JP5797636B2 (ja) 2009-04-03 2015-10-21 メリアル リミテッド ニューカッスル病ウイルスをベクターとするトリワクチン
DK2327764T3 (da) 2009-11-30 2012-04-02 United Cancer Res Inst Ny klon af Newcastle disease-virus, dens fremstilling og dens anvendelse ved medicinsk behandling af cancer
MX351643B (es) 2009-12-28 2017-10-23 Merial Ltd Antigeno ndv recombinante y usos del mismo.
WO2012018813A2 (fr) * 2010-08-02 2012-02-09 University Of Georgia Research Foundation, Inc. Virus de laryngotrachéite infectieuse (vlti) modifié et ses utilisations
BR112013007486B1 (pt) 2010-08-31 2020-01-28 Merial Ltd composição, vetor recombinante de ndv e uso da referida composição
WO2012090073A2 (fr) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Procédés et compositions pour prédire la sensibilité à la chimiothérapie
EP2694678A2 (fr) 2011-04-04 2014-02-12 Netherland Cancer Institute Procédés et compositions pour prédire une résistance à un traitement anti-cancéreux
AU2012240240A1 (en) 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
EP2701736A1 (fr) 2011-04-25 2014-03-05 Advanced Bioscience Laboratories, Inc. Protéines tronquées d'enveloppe (env) du vih, procédés et compositions associés à celles-ci
WO2012166493A1 (fr) 2011-06-01 2012-12-06 Merial Limited Administration sans aiguille de vaccins contre le vsrrp
LT2741740T (lt) 2011-08-12 2017-08-10 Merial, Inc. Biologinių produktų, ypatingai vakcinų, vakuuminis konservavimas
WO2013093629A2 (fr) 2011-12-20 2013-06-27 Netherlands Cancer Institute Vaccins modulaires, procédés et compositions qui y sont liés
WO2013138776A1 (fr) 2012-03-16 2013-09-19 Merial Limited Nouveaux procédés pour fournir une immunité de protection à long terme contre la rage chez des animaux, basés sur l'administration d'un flavivirus défectueux en termes de réplication, exprimant la rage g
US10709341B2 (en) 2012-11-21 2020-07-14 St. Jude Medical Luxembourg Holdings II S.a.r.l. Devices, systems, and methods for pulmonary arterial hypertension (PAH) assessment and treatment
HK1216006A1 (zh) 2013-03-12 2016-10-07 Boehringer Ingelheim Animal Health USA Inc. 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法
US9198908B2 (en) 2013-03-15 2015-12-01 St. Jude Medical Luxembourg Holdings Ii S.A.R.L. (“Sjm Lux Ii”) Methods for the treatment of cardiovascular conditions
EP2845904A1 (fr) * 2013-09-06 2015-03-11 Ceva Sante Animale Virus de l'herpes de la volaille recombinants et leurs utilisations
WO2016073410A1 (fr) 2014-11-03 2016-05-12 Merial, Inc. Procédés d'utilisation de formulations de vaccin par micro-aiguilles pour éliciter une immunité de protection contre le virus de la rage chez les animaux
US9981033B2 (en) 2015-06-23 2018-05-29 Merial Inc. PRRSV minor protein-containing recombinant viral vectors and methods of making and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91627A (en) * 1988-09-13 1995-08-31 Rhone Merieux Viral nucleotide sequences
WO1992003554A1 (fr) * 1990-08-24 1992-03-05 Arthur Webster Pty. Ltd. Vaccin contre le virus de la laryngotracheite infectieuse
WO1993025655A1 (fr) * 1992-06-12 1993-12-23 Genencor International, Inc. Compositions enzymatiques et procedes de production d'un aspect lave par abrasion sur du tissu denim teinte par indigo
AU2946395A (en) * 1994-06-30 1996-01-25 Board of Regents of the University of Illinois, The Recombinant infectious laryngotracheitis virus and vaccine
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
JP3964458B2 (ja) * 1995-03-23 2007-08-22 シェリング−プロウ・リミテッド 組換え型伝染性喉頭気管炎ウイルスおよびその使用

Also Published As

Publication number Publication date
AU3448797A (en) 1998-01-14
EP0914458A1 (fr) 1999-05-12
WO1997049826A1 (fr) 1997-12-31
FR2750866A1 (fr) 1998-01-16
AU739374B2 (en) 2001-10-11
AR008620A1 (es) 2000-02-09
TNSN97109A1 (fr) 2005-03-15
ZA975618B (en) 1998-12-28
MA24222A1 (fr) 1997-12-31
JP2000512844A (ja) 2000-10-03
PE52599A1 (es) 1999-07-16
CO4700303A1 (es) 1998-12-29
US6153199A (en) 2000-11-28
ID18351A (id) 1998-04-02

Similar Documents

Publication Publication Date Title
FR2750866B1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2757061B1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2758986B1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2728795B1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
DK1058558T3 (da) Rekombinante og adjuverede vacciner mod influenzavirus og herpesvirus
ZA964694B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
FR2750865B1 (fr) Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
ATE367442T1 (de) Newcastle-krankheitsvirus infektiöser klone, impfstoffe und diagnosetest
DE69730839D1 (de) Hühner polynukleotide impfstoff-formulierung
DK0870508T3 (da) Influenzavaccine
GB2337755B (en) Virus vaccine
AU4932601A (en) Recombinant parainfluenza virus expression systems and vaccines
DE60009609D1 (de) Abgasemissionsregeleinrichtung
DE69533305D1 (de) Lebende rekombinante Vogelvakzine auf eines Vogelherpesvirus gegründet, gegen Gumborokrankheit
AU7501898A (en) Live attenuated virus vaccines for equine encephalitis viruses
DZ2283A1 (fr) Composition de vaccin.
MX9202781A (es) Vacuna y metodo de tratamiento para virus de inmunodeficiencia humana.
EP0597016A4 (en) Infectious bursal disease virus recombinant poxvirus vaccine.
FR2669346B1 (fr) Vaccin a poxvirus recombinant contre le virus de la rougeole.
BR9712067A (pt) Pept¡dios imunog-nicos de v¡rus da doen-a de febre aftosa
ATE392903T1 (de) Impfstoff gegen pferdeherpesvirus
GB0100067D0 (en) Diesel exhaust system including NOx trap
DK1248650T3 (da) Forbedrede DNA-vacciner til bovint herpesvirus 1
BR9915703B1 (pt) mutante do vìrus da raiva recombinante, e, vacina anti-rábica atenuada viva.
IS6184A (is) Bóluefni gegn ISA veiru

Legal Events

Date Code Title Description
CD Change of name or company name
CJ Change in legal form
PLFP Fee payment

Year of fee payment: 20